Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21074713 | 0.86 | LMNA (0.67) | LMNAMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL31513827 | 0.84 | LMNA (0.65) | LMNAMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL11009907 | 0.84 | MEN1 (0.81) | LMNAMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL21074769 | 0.84 | HSD17B10 (0.69) | LMNAMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL21074624 | 0.83 | KDM4E (0.71) | LMNAKDM4EALDH1A1HSD17B10HPGD | |
| Difloxacin SCHEMBL148765 | 0.82 | LMNA (1.00) | LMNAMEN1KMT2AKDM4EALDH1A1 | |
| Difloxacin SCHEMBL29695838 | 0.82 | LMNA (1.00) | LMNAMEN1KMT2AKDM4EALDH1A1 | |
| Difloxacin SCHEMBL203110 | 0.81 | LMNA (0.98) | LMNAMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL21074739 | 0.80 | LMNA (0.60) | LMNAMEN1KMT2AKDM4EALDH1A1 | |
| Difloxacin SCHEMBL27973383 | 0.80 | LMNA (0.96) | LMNAMEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840549-B2 | Bisphosphonate quinolone conjugates and uses thereof | BIOVINC, LLC (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840549-B2 | Bisphosphonate quinolone conjugates and uses thereof | BIOVINC, LLC (US) | 2023-12-12 | — | — | US | disclosed |
| US-20210101920-A1 | BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-04-08 | — | — | US | disclosed |
| US-10865220-B2 | Bisphosphonate quinolone conjugates and uses thereof | BIOVINC, LLC (US) | 2020-12-15 | — | — | US | disclosed |
| US-20190169214-A1 | BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF | BIOVINC LLC (US) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865220-B2 | Bisphosphonate quinolone conjugates and uses thereof | BPGM, PHPT1, NQO2 | LMNA 2774/4885MEN1 338/4885KMT2A 4250/4885 |
| US-20190169214-A1 | BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF | BPGM, PHPT1, NQO2 | LMNA 2774/4885MEN1 338/4885KMT2A 4250/4885 |
| US-11840549-B2 | Bisphosphonate quinolone conjugates and uses thereof | BPGM, PHPT1, NQO2 | LMNA 2774/4885MEN1 338/4885KMT2A 4250/4885 |
| US-20210101920-A1 | BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF | BPGM, PHPT1, NQO2 | LMNA 2774/4885MEN1 338/4885KMT2A 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.